Can Mounjaro Cause a Heart Attack? What the Clinical Evidence Shows

What the SURMOUNT trial data found about cardiovascular events

The most direct evidence comes from SURMOUNT-1, the pivotal phase 3 trial that led to Mounjaro's UK licence for weight management. Published in the New England Journal of Medicine, it followed 2,539 adults over 72 weeks and found no statistically significant excess of major cardiovascular events (heart attacks included) in the tirzepatide groups compared with placebo. Across the wider SURMOUNT and SURPASS clinical programme, which included more than 10,000 participants in total, the cardiovascular signal remained reassuring rather than concerning.

It is worth being precise about what this means. Trial populations are selected: people with recent acute cardiovascular events or unstable heart disease were typically excluded. So the trials tell us that tirzepatide does not appear to increase cardiac risk for the kinds of patients who were enrolled. They do not yet answer every question about people with complex, active heart disease, which is exactly why a prescriber reviews each case individually.

For broader context on how Mounjaro interacts with the cardiovascular system, the Mounjaro and heart health page covers the mechanistic picture in more detail.

What the MHRA monitors and why the Black Triangle matters

Mounjaro holds a Black Triangle (▼) designation in the UK, this means the MHRA requires enhanced post-marketing surveillance because the medicine is relatively new. It does not mean the drug is considered dangerous. What it does mean is that the regulator is actively looking for patterns that trials, by their size and duration, can sometimes miss.

As of July 2026 the MHRA has not issued a Drug Safety Update linking tirzepatide to an increased risk of myocardial infarction. The safety update the MHRA did issue in January 2026 concerned acute pancreatitis across GLP-1 medicines as a class, a distinct and separately reported risk. You can report any suspected side effects via the MHRA's Yellow Card scheme; doing so contributes to the real-world evidence base that the Black Triangle designation is designed to build.

Questions about related cardiovascular topics (including what is and is not currently known) are covered on the can Mounjaro cause heart problems page, which takes a broader look at the evidence.

Who should take extra care and what to watch for

None of the above means Mounjaro is appropriate for everyone with a history of heart disease. The prescriber's job is to weigh individual risk factors: existing arrhythmias, recent cardiac events, medicines that affect heart rate, and anything else in your history that changes the picture. Mounjaro's licensed eligibility in the UK requires a BMI of 30 or above, or 27 or above alongside a weight-related condition, but meeting that threshold is a starting point, not the whole assessment.

The NHS tirzepatide medicines page lists the symptoms that need prompt medical attention: chest pain, shortness of breath, a racing or irregular heartbeat, and signs of a severe allergic reaction. These warrant a 999 call or A&E visit, not a wait-and-see approach. Separately, very severe stomach pain spreading to the back (with or without vomiting) needs urgent review because it could indicate acute pancreatitis rather than ordinary GI upset. If you want to review the full safety picture before starting treatment, the tirzepatide and heart issues page is a useful companion read.

It also bears saying: losing a meaningful amount of weight through a clinically supervised programme is itself associated with improvements in blood pressure, cholesterol and insulin sensitivity, all factors that affect cardiovascular risk. For many people, the long-term cardiovascular direction of travel on Mounjaro is likely to be positive, though individual outcomes depend on far more than the medicine alone.

How to get a proper assessment rather than a general answer

A web search can tell you what the trials found. It cannot tell you whether tirzepatide is safe for your specific heart history, current medicines, and other conditions. That requires a prescriber who reads the full picture, not a form that ticks boxes automatically. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day it is submitted, and no order is approved without that clinical step. There are no auto-approvals here.

The process is straightforward: a free consultation, same-day review, and if clinically suitable, dispatch before the end of the working day. Orders placed by noon Monday to Friday arrive with DPD the next working day, something a lot of patients plan around, whether that is a Monday after a busy weekend or the week before a holiday. If you have a heart condition in your history, that will be part of what the prescriber considers, and they may ask follow-up questions or contact your GP. You can read more about how treatment is structured on the Mounjaro treatment page, or explore the wider range of weight-loss options through our weight-loss treatments overview.

If you are already partway through a cost comparison and wondering whether the price difference between providers reflects anything meaningful about safety standards, our Mounjaro price comparison guide explains what legitimate private pricing usually includes. When you are ready to find out whether you are eligible, you can check your eligibility with a free consultation, there is no obligation and no charge for the assessment itself.